The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Ok, let’s take your point as a fair one then.
So she goes but still YOU choose to stay around here.
For what?
You’ve posted your views many times, so your opinion has been aired.
I won’t be commenting any further on anything you say, because tbh I am unclear as to your motives for being here, but each to his/her own.
Atb
Mildew, I thought you were of the opinion there is no value in this technology ? So why have not opted out and why if it’s not the billion dollar opportunity it may (or may not be) have you decided to waste your time here - who would be better placed than you to decide - and even with all the info - that your life is better spent on something you consider more valuable to you- QED
( apologies for the sarcasm, but you are like a broken record, why not just leave it unless you have an interest in this not declared?)
Hi, plenty of you guys have been here a good deal longer than me in this, and I appreciate it must feel like you have heard it all before, but I thought the interview was generally pretty positive, the delay is a matter of weeks.
I guess I have a lot yet to learn here eh ;-)
GLA
Now this may have been updated but I cannot see where, but The Guidance Notes For ISA Managers issued by HMRC,
says :
‘7.68. An investor may give an ISA manager sufficient cash to take up the offer outside the ISA, provided the ISA manager immediately transfers the investments to the investor to be held outside the ISA.’
I believe that is the relevant document. But happy to be corrected if not.
Found this earlier, thought I’d post it up, be interested to hear other’s thoughts :
https://simplywall.st/stocks/us/commercial-services/nasdaq-actg/acacia-research/news/easy-come-easy-go-how-acacia-research-nasdaqactg-shareholders-got-unlucky-and-saw-74-of-their-cash-evaporate/
Tbh I’m expecting more Mother Theresas of Message Boards coming on here, out of the goodness of their hearts, to save us from our folly ;-) an alternative view is no problem, I really welcome that, it challenges your thinking, but to my mind they over egged it yesterday, why bother spending so much time on people who have got it so wrong on a little message board? We mostly do things for our own benefit, and they and I are no different on that. I have made an investment decision to hold here after consideration, I’ll stand or fall on that choice, and live with the consequences good or not so good.
Well, personally, I will certainly concede I jumped in too high here, and yes, based on the current downward trend, this might hit 35p or possibly lower. Every time I top up, it seems it takes another dip just to **** me off a bit more, but the one thing that still seems to be holding up is the growing evidence that suggests the interferon Synairgen are using, works against Covid, at least if administered early. The question is, how effectively vis nebuliser? So, whilst the Sp continues to cause me twinges of discomfort every time I look at the bloody thing, Sng itself certainly has still not been knocked out of the park, if anything it is looking better than before. There is still a long way to market, of course, but that explains why my decision to invest and hold here still stands up for me.
Reading that article, it seems to start overtly positive about this potential vaccine and ends up qualifying this optimism rather heavily at the end with several riders that suggest it might not work and still has quite a way to go. That was my impression anyway. There’s a lot of eagerness from our politicians in power to promote something that sounds positive, even if it may not be quite be as confirmed as they are keen to suggest.
We shall see. At the moment it seems to me to be all still to play for. We should have good, well targeted data coming out shortly that will show exactly where we are in this.
Interesting article, thanks for posting.
Again, the emphasis seems to be on timing and dosage, as to the effectiveness and safety of interferon treatment. The method of delivery is also going to be key.
I think we can assume that the safety aspect of Sng is fairly robust given that it has been authorised for the home trial. Clearly in the home setting at least, it is also being administered to patients as early as is reasonable practical.
So I would suggest those two key areas can be given a tick in the sng trial.
Which leaves the last consideration, dosage. Synairgen will have been assessing this issue for a number of years and must have a very precise idea of the level of dosage they can administer via nebuliser that would have real effect.
So I see that article as generally supportive of what sng might be able to achieve here. It does refer to the individual’s response to interferon, and possible side effects, and this appears to be in line with what Synaifgen state in their consent form for the trials.